Market Cap 98.67M
Revenue (ttm) 0.00
Net Income (ttm) -26.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 469,600
Avg Vol 171,630
Day's Range N/A - N/A
Shares Out 89.70M
Stochastic %K 81%
Beta 1.93
Analysts Strong Sell
Price Target $5.17

Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...

Industry: Biotechnology
Sector: Healthcare
Phone: 267-225-7416
Address:
2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States
highnihilism
highnihilism Oct. 4 at 9:21 AM
$CNTX Context Therapeutics market cap: 98.7M | 1.10 +10.0% | opening gap +2.0% | % from open +7.8% | volume 446K | shares float 73.9M | vol/float 0
0 · Reply
NickyCollects
NickyCollects Oct. 3 at 8:05 PM
$CNTX Back to Bayside High
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:42 PM
$SEPN $CNTX $LITM $LENZ Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
VA_24
VA_24 Oct. 3 at 4:28 PM
$CNTX Hopefully steady climb until data release early 2026 1st order of business is compliance
0 · Reply
HoHoHoHum
HoHoHoHum Oct. 3 at 3:23 PM
$CNTX let’s close that gap at 1.50 soon
0 · Reply
claybridge
claybridge Oct. 3 at 2:50 PM
$CNTX why TA matters...
0 · Reply
resistancebreakers
resistancebreakers Oct. 2 at 10:54 PM
$CNTX 🪖🫡
0 · Reply
notreload_ai
notreload_ai Oct. 2 at 2:19 PM
A hidden cancer company, $CNTX, got a top rating. Its ovarian cancer drug, CTIM-76, has key data coming in 2026. https://notreload.xyz/context-therapeutics-promising-cancer-drug-developer/
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 12:40 PM
Cantor Fitzgerald updates rating for Context Therapeutics ( $CNTX ) to Overweight.
0 · Reply
resistancebreakers
resistancebreakers Sep. 20 at 5:11 PM
$CNTX Ready to explode 🔥🪖🫡☝️ Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s https://share.google/kPyM6SQyFuTfPBQ8P
1 · Reply
Latest News on CNTX
Context Therapeutics: Undervalued Cancer Fighter

Jun 10, 2025, 7:10 AM EDT - 4 months ago

Context Therapeutics: Undervalued Cancer Fighter


highnihilism
highnihilism Oct. 4 at 9:21 AM
$CNTX Context Therapeutics market cap: 98.7M | 1.10 +10.0% | opening gap +2.0% | % from open +7.8% | volume 446K | shares float 73.9M | vol/float 0
0 · Reply
NickyCollects
NickyCollects Oct. 3 at 8:05 PM
$CNTX Back to Bayside High
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:42 PM
$SEPN $CNTX $LITM $LENZ Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
VA_24
VA_24 Oct. 3 at 4:28 PM
$CNTX Hopefully steady climb until data release early 2026 1st order of business is compliance
0 · Reply
HoHoHoHum
HoHoHoHum Oct. 3 at 3:23 PM
$CNTX let’s close that gap at 1.50 soon
0 · Reply
claybridge
claybridge Oct. 3 at 2:50 PM
$CNTX why TA matters...
0 · Reply
resistancebreakers
resistancebreakers Oct. 2 at 10:54 PM
$CNTX 🪖🫡
0 · Reply
notreload_ai
notreload_ai Oct. 2 at 2:19 PM
A hidden cancer company, $CNTX, got a top rating. Its ovarian cancer drug, CTIM-76, has key data coming in 2026. https://notreload.xyz/context-therapeutics-promising-cancer-drug-developer/
0 · Reply
JarvisFlow
JarvisFlow Oct. 2 at 12:40 PM
Cantor Fitzgerald updates rating for Context Therapeutics ( $CNTX ) to Overweight.
0 · Reply
resistancebreakers
resistancebreakers Sep. 20 at 5:11 PM
$CNTX Ready to explode 🔥🪖🫡☝️ Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s https://share.google/kPyM6SQyFuTfPBQ8P
1 · Reply
claybridge
claybridge Sep. 19 at 6:44 PM
$CNTX it was a bull flag afterall...
0 · Reply
resistancebreakers
resistancebreakers Sep. 19 at 2:59 PM
$SPPL 62% since the call tomaction. Next $SGBX $NUTX $CLRO $CNTX 🔥🪖🫡☝️
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Sep. 19 at 12:59 PM
$CNTX $1.10 So far we got money here... Let's see if it breaks🫗
0 · Reply
HoHoHoHum
HoHoHoHum Sep. 19 at 10:48 AM
$CNTX hope we regain compliance and continue on to creating some value
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Sep. 19 at 8:44 AM
$CNTX The fun begins when it breaks $1.00 be patient 🥊 🥊 🥊 🥊
0 · Reply
Trendsetta69
Trendsetta69 Sep. 19 at 6:35 AM
$CNTX this will be an under the radar banger one day
0 · Reply
resistancebreakers
resistancebreakers Sep. 18 at 10:43 PM
$SGBX $CLRO $CNTX appreciating 🔥🪖🫡📯
0 · Reply
ChessGM
ChessGM Sep. 18 at 8:54 PM
$CNTX "Heads up alert! Upcoming earnings on Thursday, 9/25/2025 for $CNXC Neutral (5.4) Concentrix Corporation (NASDAQ: CNXC) Equity Research Report Concentrix Corporation has displayed a varied performance in recent times, as indicated by its strategic initiatives and financial results. The company has been actively enhancing its technological capabilities with the launch of the Agentic Operating Framework and the acquisition of SAI Digital, aiming to address AI deployment challenges and strengthen its digital commerce. These innovations underscore its commitment to maintaining leadership in customer experience management, earning the company recognition as a Leader and Star Performer in Everest Group’s 2025 CXM Services PEAK Matrix® Assessment. From a financial metrics perspective, Concentrix reported quarterly revenues of $2.42 billion, which exceeded analyst expectations by 1.2%, although earnings per share fell short. The company is navigating sector challenges, including wage inflation and regulatory scrutiny. Its price-to-earnings (P/E) ratio remains competitive within the industry, and while EPS growth has been under pressure, the company’s strategic acquisitions and technological advancements are expected to support long-term growth. Concentrix's ability to outperform in revenue generation compared to its peers is noteworthy, though the EPS miss indicates areas for operational improvement. Upcoming Earnings Report Analysis Concentrix is scheduled to release its third-quarter financial results on September 25, 2025. Historically, the company has shown resilience, often surpassing revenue expectations, although EPS results have varied. For the upcoming earnings report, analysts are cautiously optimistic, projecting steady revenue growth driven by recent strategic acquisitions and innovations. The market will closely scrutinize profit margins and operational efficiencies, given the mixed earnings performance in recent quarters. A positive surprise in EPS could significantly bolster investor confidence, while any continued shortfall may trigger concerns about the company's ability to manage cost pressures effectively. Sector Performance Concentrix operates within the business process outsourcing and consulting sector, which has faced headwinds, including increased competition from AI-driven firms and economic uncertainties. The sector has contracted by 6.4% over the past six months, contrasting with the broader market's 3.3% rise. Despite these challenges, Concentrix's strategic moves and technological advancements position it well for future growth. The potential easing of Federal Reserve policies, with prospects of interest rate cuts, could favorably impact the business services sector, potentially offsetting the recent downturn and providing a more conducive environment for growth. - Funds were net sellers of $CNXC during the previous reporting quarter. - Funds with large holdings in $CNXC include: - Invenomic Capital Management LP, MV: $36MM. Fund Rank: 76% www.invenomic.com - IEQ Capital LLC, MV: $13MM. Fund Rank: 82% - Alyeska Investments, MV: $12MM. Fund Rank: 76% - Last 10 days performance: 6% - Last 30 days performance: 14% - Last 90 days performance: 11% Some of the latest news articles: - Title: Concentrix Launches Agentic Operating Framework™ to Help Enterprises Solve Key Issues Behind Failed AI Deployments Publication Date: 9/18/2025 1:05:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/concentrix-launches-agentic-operating-framework-130500665.html?.tsrc=rss - Title: Concentrix Rises to a Leader and Star Performer in Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix® Assessment 2025 Publication Date: 9/16/2025 9:10:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/concentrix-rises-leader-star-performer-211000210.html?.tsrc=rss - Title: Concentrix Schedules Release of Third Quarter 2025 Financial Results and Investor Conference Call Webcast Publication Date: 9/11/2025 11:30:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/concentrix-schedules-release-third-quarter-113000200.html?.tsrc=rss - Title: Concentrix Named a Market Leader in Digital Marketing and Sales Services Publication Date: 9/8/2025 1:05:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/concentrix-named-market-leader-digital-130500391.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
0 · Reply
resistancebreakers
resistancebreakers Sep. 18 at 4:36 PM
$CNTX 🪖🫡☝️
0 · Reply
Nikkosi
Nikkosi Sep. 18 at 3:29 PM
$CNTX I’ll take 5$
1 · Reply
JarvisFlow
JarvisFlow Sep. 18 at 1:03 PM
Guggenheim updates rating for Context Therapeutics ( $CNTX ) to Buy, target set at 5.
0 · Reply
resistancebreakers
resistancebreakers Sep. 17 at 10:14 PM
$CNTX the more I look at it the more I can envision the breakout it's gonna have soon 😍🪖🫡
0 · Reply